RCAG
PTCT icon

Rehmann Capital Advisory Group’s PTC Therapeutics PTCT Stock Holding History

Rehmann Capital Advisory Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,250
Closed -$58.8K – 2044
2018
Q3 		$58.8K Buy
+1,250
New +$51.7K 0.01% 744

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Rehmann Capital Advisory Group's PTCT Position: Q4 2018 in Review

Rehmann Capital Advisory Group sold out of PTC Therapeutics (PTCT) in Q4 2018, closing a stake of 1,250 shares — an estimated $58.8K sold.

Rehmann Capital Advisory Group first reported a position in PTCT in Q3 2018 and held it in 1 quarter. The position peaked at $58.8K in Q3 2018. 164 funds tracked by Wall St. Rank hold PTCT as of Q4 2018.

  • Rehmann Capital Advisory Group reported no remaining PTC Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 1,250 PTC Therapeutics shares in Q4 2018, an estimated $58.8K.
  • Rehmann Capital Advisory Group first reported a position in PTC Therapeutics in Q3 2018 and held it in 1 quarter.
  • Rehmann Capital Advisory Group's PTC Therapeutics position peaked at $58.8K in Q3 2018.
  • 164 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2018.

Based on Rehmann Capital Advisory Group's 13F filing for Q4 2018, filed 12 Feb 2019.